Titan Pharmaceuticals, Inc. (de)

+0.02 (+0.81%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)24.86M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1 Million
Adjusted EPS-$0.89
See more estimates
10-Day MA$2.52
50-Day MA$2.45
200-Day MA$3.53
See more pivots

Titan Pharmaceuticals, Inc. (de) Stock, NASDAQ:TTNP

400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080-1958
United States of America
Phone: +1.650.244.4990
Number of Employees: 12


Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.